Allarity Therapeutics, Inc.
ALLR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.55 | 0.00 | -0.02 |
| FCF Yield | -957.34% | -1.94% | -601.45% | -22.81% |
| EV / EBITDA | 0.60 | -54.57 | -0.26 | -1.83 |
| Quality | ||||
| ROIC | -203.82% | 1,682.61% | -526.26% | -91.68% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.71 | 1.07 | 1.05 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -38.49% | 24.29% | -11.86% | -107.47% |
| Safety | ||||
| Net Debt / EBITDA | 0.67 | -0.09 | -0.10 | 0.71 |
| Interest Coverage | 41.72 | -36.00 | -154.54 | -53.22 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.08 |
| Cash Conversion Cycle | -169,603.33 | -83,022.70 | -19,013.46 | -7,034.86 |